在一项2a期随机临床试验的单盲扩展试验中，对斑秃患者使用利特昔替尼和布雷西替尼进行维持、撤药及再治疗。 - Suppr

Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial.

作者信息

Peeva Elena, Guttman-Yassky Emma, Banerjee Anindita, Sinclair Rodney, Cox Lori Ann, Zhu Linda, Zhu Hua, Vincent Michael, King Brett

机构信息

Pfizer, Cambridge, Massachusetts.

Icahn School of Medicine at Mt. Sinai, New York, New York.

出版信息

J Am Acad Dermatol. 2022 Aug;87(2):390-393. doi: 10.1016/j.jaad.2021.12.008. Epub 2021 Dec 13.

DOI:10.1016/j.jaad.2021.12.008

PMID:34915057

Abstract

摘要

相似文献

Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial.

J Am Acad Dermatol. 2022 Aug;87(2):390-393. doi: 10.1016/j.jaad.2021.12.008. Epub 2021 Dec 13.

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.

J Am Acad Dermatol. 2021 Aug;85(2):379-387. doi: 10.1016/j.jaad.2021.03.050. Epub 2021 Mar 20.

Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.

J Allergy Clin Immunol. 2022 Apr;149(4):1318-1328. doi: 10.1016/j.jaci.2021.10.036. Epub 2021 Dec 1.

Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib.

J Eur Acad Dermatol Venereol. 2022 Apr;36(4):602-609. doi: 10.1111/jdv.17909. Epub 2022 Jan 25.

Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial.

JID Innov. 2022 Sep 7;2(6):100156. doi: 10.1016/j.xjidi.2022.100156. eCollection 2022 Nov.

Janus kinase inhibitors for alopecia areata.

J Am Acad Dermatol. 2023 Aug;89(2S):S29-S32. doi: 10.1016/j.jaad.2023.05.049.

Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.

Expert Opin Investig Drugs. 2021 Dec;30(12):1169-1174. doi: 10.1080/13543784.2021.2012149. Epub 2021 Dec 20.

Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.

Drug Des Devel Ther. 2022 Feb 17;16:363-374. doi: 10.2147/DDDT.S334727. eCollection 2022.

Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.

Clin Drug Investig. 2023 May;43(5):325-334. doi: 10.1007/s40261-023-01260-z. Epub 2023 May 3.

A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata.

Pharmacol Res Perspect. 2024 Aug;12(4):e1204. doi: 10.1002/prp2.1204.

引用本文的文献

Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series.

Int J Womens Dermatol. 2025 Aug 13;11(3):e218. doi: 10.1097/JW9.0000000000000218. eCollection 2025 Oct.

Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review.

Dermatol Ther (Heidelb). 2025 Aug 12. doi: 10.1007/s13555-025-01517-9.

Janus kinase inhibitors for alopecia areata: a review of clinical data.

Front Immunol. 2025 May 13;16:1577115. doi: 10.3389/fimmu.2025.1577115. eCollection 2025.

Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients.

Arch Dermatol Res. 2025 Jan 18;317(1):280. doi: 10.1007/s00403-024-03784-6.

Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: A systematic review and meta-analysis.

JAAD Int. 2024 Nov 2;18:106-116. doi: 10.1016/j.jdin.2024.09.012. eCollection 2025 Feb.

[Janus kinase inhibitors for skin disorders].

Dermatologie (Heidelb). 2024 Oct;75(10):781-790. doi: 10.1007/s00105-024-05406-8. Epub 2024 Aug 30.

Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study.

Arch Dermatol Res. 2024 Jul 23;316(7):487. doi: 10.1007/s00403-024-03225-4.

Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date.

Drugs Context. 2023 Sep 25;12. doi: 10.7573/dic.2023-6-2. eCollection 2023.

Alopecia Areata: Current Treatments and New Directions.

Am J Clin Dermatol. 2023 Nov;24(6):895-912. doi: 10.1007/s40257-023-00808-1. Epub 2023 Aug 22.

Ritlecitinib: First Approval.

Drugs. 2023 Sep;83(14):1315-1321. doi: 10.1007/s40265-023-01928-y.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial.

作者信息

Peeva Elena, Guttman-Yassky Emma, Banerjee Anindita, Sinclair Rodney, Cox Lori Ann, Zhu Linda, Zhu Hua, Vincent Michael, King Brett

机构信息

Pfizer, Cambridge, Massachusetts.

Icahn School of Medicine at Mt. Sinai, New York, New York.

出版信息

J Am Acad Dermatol. 2022 Aug;87(2):390-393. doi: 10.1016/j.jaad.2021.12.008. Epub 2021 Dec 13.

DOI:10.1016/j.jaad.2021.12.008

PMID:34915057

Abstract

摘要

相似文献

Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial.

J Am Acad Dermatol. 2022 Aug;87(2):390-393. doi: 10.1016/j.jaad.2021.12.008. Epub 2021 Dec 13.

A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.

J Am Acad Dermatol. 2021 Aug;85(2):379-387. doi: 10.1016/j.jaad.2021.03.050. Epub 2021 Mar 20.

Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.

J Allergy Clin Immunol. 2022 Apr;149(4):1318-1328. doi: 10.1016/j.jaci.2021.10.036. Epub 2021 Dec 1.

Characterizing the relationships between patient-reported outcomes and clinician assessments of alopecia areata in a phase 2a randomized trial of ritlecitinib and brepocitinib.

J Eur Acad Dermatol Venereol. 2022 Apr;36(4):602-609. doi: 10.1111/jdv.17909. Epub 2022 Jan 25.

Safety and Efficacy of Ritlecitinib and Brepocitinib in Alopecia Areata: Results from the Crossover Open-Label Extension of the ALLEGRO Phase 2a Trial.

JID Innov. 2022 Sep 7;2(6):100156. doi: 10.1016/j.xjidi.2022.100156. eCollection 2022 Nov.

Janus kinase inhibitors for alopecia areata.

J Am Acad Dermatol. 2023 Aug;89(2S):S29-S32. doi: 10.1016/j.jaad.2023.05.049.

Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.

Expert Opin Investig Drugs. 2021 Dec;30(12):1169-1174. doi: 10.1080/13543784.2021.2012149. Epub 2021 Dec 20.

Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.

Drug Des Devel Ther. 2022 Feb 17;16:363-374. doi: 10.2147/DDDT.S334727. eCollection 2022.

Safety of Janus Kinase inhibitors in Patients with Alopecia Areata: A Systematic Review.

Clin Drug Investig. 2023 May;43(5):325-334. doi: 10.1007/s40261-023-01260-z. Epub 2023 May 3.

A phase 2a study investigating the effects of ritlecitinib on brainstem auditory evoked potentials and intraepidermal nerve fiber histology in adults with alopecia areata.

Pharmacol Res Perspect. 2024 Aug;12(4):e1204. doi: 10.1002/prp2.1204.

引用本文的文献

Discontinuation and restart of Janus kinase inhibitors due to pregnancy in alopecia areata: a case series.

Int J Womens Dermatol. 2025 Aug 13;11(3):e218. doi: 10.1097/JW9.0000000000000218. eCollection 2025 Oct.

Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review.

Dermatol Ther (Heidelb). 2025 Aug 12. doi: 10.1007/s13555-025-01517-9.

Janus kinase inhibitors for alopecia areata: a review of clinical data.

Front Immunol. 2025 May 13;16:1577115. doi: 10.3389/fimmu.2025.1577115. eCollection 2025.

Ritlecitinib, a JAK3 /TEC inhibitor, modulates the markers of celiac autoimmunity in alopecia areata and vitiligo patients.

Arch Dermatol Res. 2025 Jan 18;317(1):280. doi: 10.1007/s00403-024-03784-6.

Risk of infections during treatment with oral Janus kinase inhibitors in randomized placebo-controlled trials: A systematic review and meta-analysis.

JAAD Int. 2024 Nov 2;18:106-116. doi: 10.1016/j.jdin.2024.09.012. eCollection 2025 Feb.

[Janus kinase inhibitors for skin disorders].

Dermatologie (Heidelb). 2024 Oct;75(10):781-790. doi: 10.1007/s00105-024-05406-8. Epub 2024 Aug 30.

Dupilumab induces hair regrowth in pediatric alopecia areata: a real-world, single-center observational study.

Arch Dermatol Res. 2024 Jul 23;316(7):487. doi: 10.1007/s00403-024-03225-4.

Efficacy and safety of baricitinib in patients with alopecia areata: evidence to date.

Drugs Context. 2023 Sep 25;12. doi: 10.7573/dic.2023-6-2. eCollection 2023.

Alopecia Areata: Current Treatments and New Directions.

Am J Clin Dermatol. 2023 Nov;24(6):895-912. doi: 10.1007/s40257-023-00808-1. Epub 2023 Aug 22.

Ritlecitinib: First Approval.

Drugs. 2023 Sep;83(14):1315-1321. doi: 10.1007/s40265-023-01928-y.

Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Maintenance, withdrawal, and re-treatment with ritlecitinib and brepocitinib in patients with alopecia areata in a single-blind extension of a phase 2a randomized clinical trial.

作者信息

机构信息

出版信息

相似文献

引用本文的文献